Background: Transmitted drug-resistance (TDR) remains a critical aspect for the management of HIV-1-infected individuals. Thus, studying the dynamics of TDR is crucial to optimize HIV care.
Introduction
HIV-1 transmitted drug resistance (TDR) is a clinical and public health issue due to its role in compromising the response to ART at the individual and population level, [1] [2] [3] [4] limiting the antiretroviral regimen options. As a result, European and US guidelines recommend genotypic resistance testing in HIV-infected individuals at entry into care (regardless of whether ART will be initiated immediately). 5, 6 To date, estimates of TDR rates vary across the world and range from 3.4% to 25.2% in the USA, [7] [8] [9] and from 7.5% to 11.7% in Europe. [10] [11] [12] [13] Despite the general decreasing trend of TDR in both the United States and Europe in the last few years, an alarming increase has been noticed in some specific settings. 7, 14 In this regard, in several countries different frequencies of TDR, according to subtypes and risk factors, have been observed, especially in the last decade, when an increase in non-B subtypes and circulating recombinant forms (CRFs) has been reported. [15] [16] [17] This increase in non-B subtypes occurred in conjunction with associated epidemiological changes such as waves of migration from low-income to middle-income areas, 18, 19 and the increase of HIV transmission rate among MSM, 20, 21 which to date accounts for at least 43% of new HIV-1 cases. 22, 23 In this scenario, studying the linkages between viruses through transmission cluster (TC) analysis can be used to provide an in-depth understanding of TDR dynamics and resistance spread. 11, 24, 25 For these reasons, this study aims to characterize the dynamics and phylogenetic relationships of TDR and subtypes among a large cohort of HIV-1-infected individuals diagnosed in Italy from 2000 to 2014.
Methods

Study population
Between 2000 and 2014, plasma samples from 4323 newly diagnosed HIV-1-infected individuals, naive to ART, attending three different counselling and testing centres in north and central Italy, were tested for antiretroviral drug resistance (DR) genotyping, according to routine clinical practice.
Individuals were defined as recently infected by: (i) clinical/laboratory signs of primary HIV infection (HIV-1 RNA levels .10000 copies/mL and negative or indeterminate HIV-1 antibody test); (ii) a documented negative HIV-1 test performed within 6 months before the HIV-1 diagnosis; and (iii) an antibody avidity index 0.80 (test performed only in clinically AIDSfree individuals). 26, 27 All clinical and virological information used in this study was collected within 8 weeks after the initial HIV-1 diagnosis (range of weeks after HIV-1 diagnosis: 0-8). 
Ethics
HIV-1 genotyping
For all individuals HIV-1 pol [containing the full-length protease (PR) and the first 335 reverse transcriptase (RT) codons] sequences were available at the time of diagnosis (range 0-2 months from diagnosis). HIV-1 pol genotype analyses were performed on plasma samples, as previously described. 28 All samples were processed immediately upon arrival in clinical laboratories.
HIV-1 subtyping
For each HIV-1-infected individual, the HIV-1 subtype was determined. pol sequences were aligned and compared with reference sequences for the major HIV-1 subtypes, available at: https://www.hiv.lanl.gov/content/se quence/NEWALIGN/align.html#ref, using CLUSTAL X. The sequences were then manually edited with the Bioedit program, and gaps were removed from the final alignment. Subtype or CRF assignments were achieved by constructing phylogenetic trees using the neighbour-joining (NJ) method. 29 Distances were calculated using MEGA 6 based on the Kimura two-parameter model. 30 The reliability of the branching orders was assessed by bootstrap analysis of 1000 replicates. TDR was evaluated by considering the WHO-2009 list  31 with the additional  RT mutations K65E/N, E138G/K/Q/R, V179L, G190Q, T215N, H221Y, F227C and M230I, reported in the International AIDS Society (IAS) list 32 and/or the Stanford 2017 database (https://hivdb.stanford.edu/, last updated 7 February 2017).
Definition of TDR
HIV-1 strains were defined as resistant if carrying at least one TDR mutation.
Transmission cluster analysis
TCs, including pairs (2 individuals) and clusters (3 individuals) were first deduced by the NJ method by using all the 4323 pol sequences obtained via routine clinical practice in the period 2000-14. To avoid any possibility of cross-contamination, identical sequences amplified in the same run were excluded. To avoid the influence of convergent evolution at antiretroviral DR mutations, sequences were stripped at positions related to DR. Only clusters with a bootstrap value .90% and an average genetic distance ,0.015 were selected. 33 The robustness of the TCs was further tested using the maximum likelihood (ML) method and a Bayesian analysis.
The ML tree was inferred with the general time-reversible nucleotide substitution model (GTR) with gamma-distribution among site rate heterogeneity, a proportion of invariable sites (GTR ! I ! U 5 ) 34 and 1000 bootstrap replicates (using the RaxML software, available at http://sco.h-its.org/exe lixis/web/software/raxml/index.html). TCs were recognized by Cluster Picker, 35 retrieved at http://hiv.bio.ed.ac.uk/software.html, based on a bootstrap value .90% and an average genetic distance ,0.015. The tree was rooted using a midpoint rooting by FigTree software version 1.4.2.
The Bayesian phylogenetic tree was reconstructed with MrBayes, 36 using a GTR ! I ! U 5 . A Monte Carlo Markov chain search was run for 5%10 6 generations with the trees sampled every 100th generation (with a burn-in of 50%). 37 Statistical support was obtained by calculating the posterior probability of each monophyletic clade, and an a posteriori consensus tree was generated after 50% burn-in. Clades were considered epidemiological clusters only if a posterior probability of 1 was inferred.
Statistical analysis
To evaluate potential differences in the prevalence of TDR according to subtype, the v 2 test or Fisher's exact test was used, as appropriate. Potential differences in the prevalence of TDR, subtypes and risk factor over the years 2000-14 were evaluated by time-series analysis for linear trend. The 251 individuals diagnosed between 2000 and 2004 were gathered together in a single time period defined as ,2005, in order to have a similar numerical distribution of individuals over the years.
Factors associated with TDR (in both the overall population and within clusters) were evaluated by uni-multivariable logistic regression analysis, using as confounders gender, age, subtype, risk factor, nationality, year of diagnosis and sequencing, viraemia and CD4 count at sequencing, type of infection and to be part of TC.
For all statistical tests, the level of significance for the evaluation of two-sided P values was set at a " 0.05. All the analyses were performed by using the R open source statistical environment (version 3.3.1) and SPSS (version 23) for Windows (SPSS Inc., Chicago, Illinois).
Results
Patient characteristics
A total of 4323 individuals newly diagnosed with HIV-1 from 2000 through 2014 were included ( Table 1 ). The majority of these individuals (3468, 80.2%) were male, Italian (3115, 72.1%) and MSM (1824, 42.2%). Recent infections accounted for the 22.5% of the individuals for whom state of infection was available.
The majority (N " 2992, 69.2%) of the individuals were infected with a B subtype, followed by CRF02_AG (329, 7.6%), F1 (248, 5.7%), Fabeni et al. 
Prevalence and temporal trend of transmitted drug resistance
The overall prevalence of TDR in the period 2000-14 was 8.8% (N " 382). The majority of individuals carried a single mutation (N " 266, 69.6%). TDR was higher in B subtype-infected individuals than in those infected with non-B subtypes (9.7% versus 6.9%, P " 0.003). By analysing individuals carrying TDR and with an available state of infection, 38 (26.2%) were in recent infections.
Of these, 24 (63.1%) were MSM and 12 (31.6%) were heterosexual transmissions.
Analysing the TDR temporal trend, in B subtype-infected individuals resistance to any drug class decreased over time with a slight trend towards significance (,2005-14: 13.4%-8.1%, P " 0.156), with a significant decrease in DR to PIs (,2005-14: 5.0%-1.6%, P " 0.001) (Figure 2a ). In contrast, among the 1331 non-B subtypeinfected individuals, TDR to any drug class significantly increased over time (,2005-14: 2%-7.1%, P " 0.018) (Figure 2b ). Figures S1 and S2 , available as Supplementary data at JAC Online). Of these 62 TCs, 48 (B subtype: N " 35; non-B subtypes: N " 13) were pairs, and 14 (B subtype: N " 9; non-B subtypes: N " 5) were TCs with 3 individuals. Moreover, among these 62 TCs, 24 (38.7%) included a single patient with TDR, while 32 (51.6%) were entirely composed of individuals carrying resistance (Table S1) .
Transmission clusters and their role in TDR
By analysing the rate of TDR clustering over time, the presence of TDR within TCs dramatically increased over the years, reaching 35.5% of the overall TDR in 2014 (,2005-14: 14.3%-35.5%, P " 0.005) (data not shown).
Considering the characteristics of the 190 subjects involved in the 62 TDR TCs, 86.3% (N " 165) were male, 79.5% (N " 151) were Italians and 49.5% (N " 94) were MSM (Table S1) 
Prevalence of TDR mutations in the overall population and in the TCs
The prevalence of TDR mutations in the overall population and in the TCs according to drug classes and subtypes is shown in Figure 3 .
Analysing resistance in HIV-1 B subtype-infected individuals, 4.5% of them (134/2992) harboured mutations associated with resistance to NRTIs; of note, 1.4% of these individuals (41/2992) were involved in TCs. The NRTI mutation T215rev had the highest prevalence in the overall B subtype-infected population (3.1%: individuals involved in TCs, 0.9%; individuals not included in TCs, 2.2%), followed by M41L (1.6%: 0.6% and 1%) and L210W (1.0%: 0.3% and 0.7%). Interestingly, in non-B subtype-infected individuals NRTI mutations accounted only for 1.4% of the overall population; none of these mutations were found in TCs. Fabeni et al.
Concerning NNRTI resistance, 4.1% (124/2992) and 4.2% (56/1331) of the B and non-B subtype infected individuals carried at least one mutation to this class, respectively. Of note, 1.0% of B (31/2992) and 1.9% of non-B (25/1331) subtype-infected individuals were involved in TCs.
In both B and non-B subtype groups, the most prevalent NNRTI mutations (either in individuals included or in those non-included in TCs) were K103N (B subtype: 2.1%; non-B subtype: 1.7%) and E138G/K (0.7%; 1.7%), followed by K101E (0.7%; 0.8%).
In the overall B and non-B subtype groups, mutations associated with resistance to PI were observed with a prevalence 2.5% (individuals involved in TCs: 0.6%; individuals not included in TCs: 1.9%) and 2.0% (0.7%; 1.3%); Q58E was the most prevalent PI mutation found both in the overall B and non-B groups.
Factors associated with TDR
Univariate and multivariate logistic regression models were performed to identify potential predictors of TDR (Figure 4) .
The results showed that in our population, being part of TCs was not a predictor of TDR [adjusted odds ratio, AOR (95% CI): 0.92 (0.71-1.18); P " 0.495]. Whereas there was a negative association between the presence of TDR and individuals infected with a CRF02_AG recombinant form compared with those infected with a B subtype [AOR (95% CI): 0.45 (0.26-0.80); P " 0.006]. These results were also confirmed by using the type of infection as a confounder (N " 1794), (Figure 4b ).
Discussion
We have here described molecular and epidemiological characteristics of 4323 HIV-1 drug-naive infected individuals attending three different counselling and testing centres in north and central Italy in the period 2000-14 to gain further insights into the time trends of subtype distribution, TDR and TCs.
The first finding concerns the epidemiological changes occurring in Italy over the last decade. In particular, our study, which covers a period of 14 years, observed a higher prevalence of non-B subtypes in newly diagnosed individuals, and, mainly, in subjects originating from Italy. This is in line with the important increase of non-B subtypes and CRFs reported in several European countries 15, [38] [39] [40] [41] [42] [43] during the last decade. This increase in non-B subtypes occurred in conjunction with associated epidemiological changes, such as waves of migration from low-income to middle-income areas, 18, 19 and an increase in HIV transmission among MSM. 20, [44] [45] [46] [47] [48] [49] In line with this phenomenon, our study also shows that the non-B epidemic is characterized by a shift in the prevalent modality of infection and nationality, and also in the setting of recent infection. Based on these findings, we analysed the dynamics of TDR according to these temporal epidemiological changes.
The overall TDR prevalence was 8.8%, consistent with other European studies, [11] [12] [13] 50, 51 but lower than that observed in several US settings. 8, 9 However, an alarming temporal TDR increase was observed in subjects infected with non-B subtype HIV-1 (,2005-14: 2.0%-7.1%, P " 0.018), different from that observed in HIV-1 B-infected individuals. This increasing trend of TDR in non-B subtypes observed in our population coincided with an increase in recent infections characterized by a homosexual transmission route. This finding was also reported by a recent paper published by our group, 20 highlighting circulation of TDR TCs characterized by non-B MSM. Other European studies confirmed the strict relationship between the increasing trend of TDR and the MSM route, in non-B infections, 49, 51 but also in subtype B infections. 11 These data highlight the importance of studying and monitoring local epidemics and suggests TDR prevalence may vary within subtypes and risk factors.
By assessing TDR prevalence according to drug class, we found that the increasing trend in non-B TDR is mainly linked to the detection of NNRTI DR, as also suggested by the high prevalence of K103N and K101E in the overall and TC populations. The same linear increase was observed in the SPREAD study that included data up to 2007, 52 in which the authors suggested a potential association with the frequent use of NNRTI in the first-line regimens. Indeed, from 2009 onwards, the most commonly prescribed regimen was the potent combination tenofovir ! emtricitabine ! efavirenz, and up until 2012, no other available regimens had proven superior to this one with respect to the virological response.
The second aim of this study was to evaluate the contribution of TCs in the spread of the HIV epidemic and TDR. In this study, the rate of sequences segregating in clusters is 28.0%, similar to that reported in France, 40 the Basque country 53 and the UK, 54 and quite low with respect to that reported in the Nordic European countries 41 and in the Swiss cohort. 54 The presence of TDR within TCs accounted for 29.3% of the entire TDR population. The contribution of TCs to TDR observed was superimposable onto those reported by other European and US studies, 7, 11 especially when a more stringent criterion of genetic distance for TC detection was applied.
11 Most importantly, our study indicates that the contribution of TCs to the spread of DR has increased in the last few years, with a peak in 2014, suggesting that a public health policy targeting early diagnoses is needed. Since multivariate logistic regression models did not identify factors associated with TDR, with the exception of a negative role of CRF02_AG, we were unable to identify positive predictors of DR, a result similar to that observed in other studies performed in Europe. 11, 14 In line with other European cohorts, our TDR TCs frequently involved individuals with different subtypes and nationalities. 11, 20 This implies that migration plays an important role in the local spread of B and non-B subtypes, but also of TDR, supporting an extensive intermixing of the HIV-1 epidemic between locals and immigrants.
Moreover, as reported above, the spread of non-B subtypes in the local epidemic and in TCs was an increasing phenomenon, mainly related to the MSM route that often involves Italians. The contribution of MSM in TCs was also evident when recent infections were considered. In particular, 30.3% of MSM in our TC population was recently infected and this prevalence increased to 44.4% when non-B TCs were considered. The high propensity of MSM for clustering was previously reported by Ragonnet-Cronin et al., 54 who found a predominant MSM contribution in TCs for both the UK HIV Drug Resistance Database and the Swiss HIV Cohort Study.
Regarding TDR in TCs, NRTIs, and in particular the T215 revertant mutations, were predominant in B subtype TCs, confirming the frequent transmission of viruses containing revertants at position 215 in Europe. 11, 33 In contrast, we did not find any resistance mutations associated with thymidine analogues (such as T215rev, M41L and L210W) in non-B TCs. This finding may be explained by the more recent date of diagnosis found in non-B versus B subtypes, occurring when the use of thymidine analogues was no longer recommended.
In non-B TCs, the predominant role in the spread of TDR was played by NNRTI mutations (in particular K103N, E138K and K101E). In fact, one of the most important TCs carried K103N (shown in Figure S2 ). This cluster involved both heterosexual and homosexual males originating from Italy. The latest diagnosis date was 2014, suggesting that in our local epidemic this mutation was involved in a recent spread.
Thus, continuous monitoring of the role of NNRTI mutations in TCs is required to establish their impact on current HIV epidemics.
As with any other observational study, our data may have some limitations. First, our study population might not be representative of the overall Italian population. In particular, looking at the HIV/AIDS surveillance reports published by ECDC and the WHO Regional Office for Europe (WHO/Europe), 22 37023 new diagnoses of HIV-1 were reported in Italy from 2005 to 2015. Thus, the 4323 HIV-1 diagnoses reported in our study in the same time period represent 11.7% of the overall HIV-1-infected Italian population. Focusing attention on the new diagnoses found in north and central Italy (N " 22798), this coverage increased to 19.0% of the overall HIV-1-infected individuals. 55 However, the increasing prevalence of non-B subtypes and MSM found in our population over time (also in the setting of recent infections) is confirmed by the high prevalence of immigrants and MSM reported in 2015, 55 thus suggesting that our samples broadly matched the characteristics of the whole HIV-1-infected Italian population. The increasing trend of non-B and MSM was also reported by several European studies, 41, 44, 48, 49 suggesting a good reproducibility of our results with respect to large European contexts, and supporting the role of migration in the epidemiological changes described above.
Second, this study did not evaluate TDR to other classes of antiretroviral drugs, such as integrase inhibitors. As the use of these agents increases and is recommended by national and international guidelines, 5, 56, 57 surveillance for TDR must be included. Finally, the potential association between demographic data and TDR could not be evaluated in depth because some information was not available.
In conclusion, this study proves that complementing information on individuals' demographics, modality of transmission, viral and clinical parameters, with results obtained through phylogenetic analysis, creates an added value in the understanding of local HIV epidemics. In particular, with this study, we were able to show that individuals infected with B subtype viruses and individuals Dynamics of HIV-1 transmitted drug resistance in Italy JAC infected with non-B subtypes represent significantly different populations, with different routes of transmission and different trends of TDR. This study also suggests that HIV-1 non-B subtypes in Italy may have a primary role in the spread of drug-resistant strains, which have to date mainly been associated with the B subtype. Indeed, TDR and complex TCs containing drug-resistant strains, to date observed mainly in the context of B subtype infections, dramatically increased in HIV-1 non-B-infected individuals.
Overall, this deeper analysis can contribute to the design of well-targeted prevention and control programmes, and to reinforce the current recommendation for both baseline resistance testing to guide treatment decisions and early treatment in order to prevent transmission of HIV drug resistance. 5, 6 
